We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Prof. Elisabetta Rovida, Molecular Oncology & Cell Signalling. Associate Professor University of Florence.
Mitogen-activated protein kinase (MAPK) signalling is frequently dysregulated in cancer and is of considerable interest as a therapeutic target. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), the two main primary liver malignancies, remain difficult to treat, making the identification of additional therapeutic targets a pressing need. This seminar will discuss current approaches to targeting MAPK signalling in liver tumours and present our group’s research on the role of ERK5 in HCC and CCA.Our work has identified a key role for the ERK5 pathway in HCC development and growth, as well as in maintaining the malignant phenotype of CCA cells through interactions with the tumour microenvironment. Furthermore, we are investigating how ERK5 cross-talks with other pathways that support cancer cell survival and proliferation to identify combination treatments that may prevent resistance mechanisms. In HCC cells, ERK5 inhibition is associated with compensatory upregulation of EGFR signalling, while studies in intrahepatic CCA point to a crucial role for ERK5 in the response to hypoxia. Together, these findings suggest that targeting ERK5, either as a monotherapy or in combination with other pathway inhibitors, may expand the therapeutic optionsfor liver cancer.
Host: Dr. José Miguel Lizcano de Vega, Head of group Protein kinases in cancer research (VHIR)
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.